Toggle light / dark theme

Researchers at MIT and Harvard University have designed a way to selectively turn on gene expression in target cells, including human cells. Their technology can detect specific mRNA sequences (represented in the center of the illustration), which triggers production of a specific protein (bottom right). Credit: Jose-Luis Olivares, MIT, with figures from iStockphoto.

“This brings new control circuitry to the emerging field of RNA therapeutics, opening up the next generation of RNA therapeutics that could be designed to only turn on in a cell-specific or tissue-specific way,” says James Collins, the Termeer Professor of Medical Engineering and Science in MIT’s Institute for Medical Engineering and Science (IMES) and Department of Biological Engineering and the senior author of the study.

This highly targeted approach, which is based on a genetic element used by viruses to control gene translation in host cells, could help to avoid some of the side effects of therapies that affect the entire body, the researchers say.

A commonly available oral diuretic pill approved by the U.S. Food and Drug Administration may be a potential candidate for an Alzheimer’s disease treatment for those who are at genetic risk, according to findings published in Nature Aging. The research included analysis showing that those who took bumetanide — a commonly used and potent diuretic — had a significantly lower prevalence of Alzheimer’s disease compared to those not taking the drug. The study, funded by the National Institute on Aging (NIA), part of the National Institutes of Health, advances a precision medicine approach for individuals at greater risk of the disease because of their genetic makeup.

The research team analyzed information in databases of brain tissue samples and FDA-approved drugs, performed mouse and human cell experiments, and explored human population studies to identify bumetanide as a leading drug candidate that may potentially be repurposed to treat Alzheimer’s.

“Though further tests and clinical trials are needed, this research underscores the value of big data-driven tactics combined with more traditional scientific approaches to identify existing FDA-approved drugs as candidates for drug repurposing to treat Alzheimer’s disease,” said NIA Director Richard J. Hodes, M.D.

An international team of researchers wants to find people who are genetically resistant to SARS-CoV-2, in the hope of developing new drugs and treatments.


Imagine being born naturally resistant to SARS-CoV-2, and never having to worry about contracting COVID-19 or spreading the virus. If you have this superpower, researchers want to meet you, to enrol you in their study.

As described in a paper in Nature Immunology1 this month, an international team of scientists has launched a global hunt for people who are genetically resistant to infection with the pandemic virus. The team hopes that identifying the genes protecting these individuals could lead to the development of virus-blocking drugs that not only protect people from COVID-19, but also prevent them from passing on the infection.

“It’s a terrific idea,” says Mary Carrington, an immunogeneticist at the Frederick National Laboratory for Cancer Research in Bethesda, Maryland. “Really, a wise thing to do.”

The non-E5 made rats healthier with a small increase in lifespan. The E5 part 2 is still ongoing with rats at 31 months that generally at most live 36 months.


In this video we give a brief update on the parallel experiments being conducted by Dr Katcher and Professor Goya. In these studies they are injecting E5 and young blood plasma into rats in repeatedly to see if the maximum lifespan can be extended.

The newsletter is here.

Track code: TD-3

Abstract:
Solar Sails are at the same stage of engineering development as electric motors were in the 1830’s. Each attribute of solar flux has been examined in isolation, such as photon, proton, plasma, and electrodynamic systems. This talk recommends designing a simple baseline system that converges multiple propulsion methods into optimized systems, as is currently done with electric motors. Many convergences can come from this solution space. Once a baseline design is created, AI genetic algorithms can “flight test” and refine the designs in simulation to adjust proportions and geometry. Once a base design is refined, a second AI evolution pass would design fleet systems that flock like birds to optimize performance. These could fly as a protective shield around Mars crewed fleets, provide space based solar power, deploy rapid reaction probes for interstellar comets, and be used in NEO asteroid mining. In the long term, fleets of solar energy management vehicles can provide orbital Carrigan event protection and Martian solar wind protection for terraforming. This talk is also a case study in how technology revolutions happen, and how to accelerate the creation and democratization of technical solutions.

From the 24th Annual International Mars Society Convention, held as a Virtual Convention worldwide on the Internet from October 14–17, 2021. The four-day International Mars Society Convention, held every year since 1,998 brings together leading scientists, engineers, aerospace industry representatives, government policymakers and journalists to talk about the latest scientific discoveries, technological advances and political-economic developments that could help pave the way for a human mission to the planet Mars.

Conference Papers and some presentations will be available on www.MarsPapers.org.

Circa 2018


The secrets to immortality may lie in an unexpected place — fruit fly stem cells. Researchers led by Howard Hughes Medical Institute (HHMI) Investigator Yukiko Yamashita have found that some stem cells have a genetic trick to remain young forever across generations. While some areas of the fruit fly genome get shorter as they age, some reproductive cells are able to fix that shortening. Once observed only in yeast, this work, reported in eLife, has revealed more about aging, and how some cells can avoid it.

This work focused on critical genes in ribosomal DNA, rDNA. Ribosomes are cellular organelles that act as protein factories. That rDNA is repeated in several areas of the genome because many ribosomes are needed to make all of the proteins the body needs. Five chromosomes each have spots with hundreds of copies of rDNA. However, that type of redundant sequence can be difficult for cells to replicate accurately every time cell division happens.

An artificial intelligence (AI)-based technology rapidly diagnoses rare disorders in critically ill children with high accuracy, according to a report by scientists from University of Utah Health and Fabric Genomics, collaborators on a study led by Rady Children’s Hospital in San Diego. The benchmark finding, published in Genomic Medicine, foreshadows the next phase of medicine, where technology helps clinicians quickly determine the root cause of disease so they can give patients the right treatment sooner.

“This study is an exciting milestone demonstrating how rapid insights from AI-powered decision support technologies have the potential to significantly improve patient care,” says Mark Yandell, Ph.D., co-corresponding author on the paper. Yandell is a professor of human genetics and Edna Benning Presidential Endowed Chair at U of U Health, and a founding scientific advisor to Fabric.

Worldwide, about seven million infants are born with serious genetic disorders each year. For these children, life usually begins in intensive care. A handful of NICUs in the U.S., including at U of U Health, are now searching for genetic causes of disease by reading, or sequencing, the three billion DNA letters that make up the human genome. While it takes hours to sequence the whole genome, it can take days or weeks of computational and manual analysis to diagnose the illness.

Circa 2019 😀


Because they can process massive amounts of data, computers can perform analytical tasks that are beyond human capability. Google, for instance, is using its computing power to develop AI algorithms that construct two-dimensional CT images of lungs into a three-dimensional lung and look at the entire structure to determine whether cancer is present. Radiologists, in contrast, have to look at these images individually and attempt to reconstruct them in their heads. Another Google algorithm can do something radiologists cannot do at all: determine patients’ risk of cardiovascular disease by looking at a scan of their retinas, picking up on subtle changes related to blood pressure, cholesterol, smoking history and aging. “There’s potential signal there beyond what was known before,” says Google product manager Daniel Tse.

The Black Box Problem

AI programs could end up revealing entirely new links between biological features and patient outcomes. A 2019 paper in JAMA Network Open described a deep-learning algorithm trained on more than 85,000 chest x-rays from people enrolled in two large clinical trials that had tracked them for more than 12 years. The algorithm scored each patient’s risk of dying during this period. The researchers found that 53 percent of the people the AI put into a high-risk category died within 12 years, as opposed to 4 percent in the low-risk category. The algorithm did not have information on who died or on the cause of death. The lead investigator, radiologist Michael Lu of Massachusetts General Hospital, says that the algorithm could be a helpful tool for assessing patient health if combined with a physician’s assessment and other data such as genetics.

Summary: Researchers have linked Fragile X and SHANK3 deletion syndrome, two disorders associated with autism, to specific microscopic walking patterns.

Source: Rutgers.

Rutgers researchers have linked the genetic disorders Fragile X and SHANK3 deletion syndrome – both linked to autism and health problems – to walking patterns by examining the microscopic movements of those wearing motion-sensored sneakers.